ProCE Banner Activity

IFM 2017-03: Phase III Trial of Daratumumab + Lenalidomide vs Lenalidomide + Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma

Slideset Download
Conference Coverage

Among frail patients with newly diagnosed multiple myeloma, a dexamethasone-sparing regimen of daratumumab plus lenalidomide was associated with higher response rates and MRD negativity rates vs lenalidomide plus dexamethasone and had a favorable safety profile.

Released: December 16, 2022

Expiration: December 15, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen